SD-SAB-BIOTHERAPEUTICS
16.12.2020 13:29:11 CET | Business Wire | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced the appointment of Mani Mohindru, PhD, and Mervyn Turner, PhD to its Board of Directors.
“We are excited to welcome Drs. Mohindru and Turner to our Board of Directors. Each industry executive brings a wealth of corporate strategy, drug development and financial expertise,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “Both Drs. Mohindru and Turner are joining SAB at a pivotal time as we continue to advance a new class of immunotherapies that leverage the native human immune response and match the evolution of human disease. We look forward to their contributions as we develop our robust pipeline, spanning multiple therapeutic areas, using our novel technology platform.”
Dr. Mohindru is a senior biopharmaceutical executive with several years of industry leadership as well as Wall Street experience. Most recently, she was the CEO of CereXis, a clinical-stage biopharmaceutical company developing treatments for rare tumors. Previously, Dr. Mohindru was Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics (Nasdaq: CARA), a company focused on developing therapies for pruritus and pain. Earlier, she served as Chief Strategy Officer at Curis, Inc. (Nasdaq: CRIS), where she was instrumental in the development of overall strategy for its oncology focused pipeline. Dr. Mohindru also spent several years as an equity research analyst covering the biotechnology sector at ThinkEquity, LLC, Credit Suisse and UBS. She also co-founded Immtox LLC, a privately-held biotechnology company, and was a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health). Currently, she also serves as a Member of the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Dr. Mohindru received her PhD in Neurosciences from Northwestern University.
Dr. Mervyn Turner has nearly 35 years of experience in pharmaceutical drug discovery, research and development, licensing and business development, emerging markets strategy development and implementation. He currently operates his own consulting firm, MJ Turner Consulting, where he counsels biotech, pharma, venture capital and investment banking firms. He spent 27 years at Merck & Co. Inc., holding positions of increasing responsibility in Merck Research Laboratories before joining the company’s Executive Committee as Chief Strategy Officer. Since his retirement from Merck & Co., he is currently an Advisor to Bay City Capital, a San Francisco-based venture firm, to Bridge Medicines, a commercial incubator for early stage innovation based in New York City, and to Adagene, a China-based therapeutic antibody company. Dr Turner is also a member of the Board of EnGeneIC (Sydney, Australia), and the Chairman of the Board of LUNAC. He also serves on the Scientific Advisory Boards of Blade Therapeutics and Spinogenix. Additionally, Dr. Turner is a Senior Advisor to the Healthcare group of Lazard, a leading financial services and investment banking firm. He holds his PhD in Chemistry from the University of Sheffield.
“I am excited to have the opportunity to join the Board of SAB, to help foster the adoption of the company’s unique capabilities in meeting the therapeutic needs of both the current, and future pandemics,” said Mervyn Turner, PhD. “I also look forward to helping to drive the SAB platform into novel therapeutic areas outside infectious disease, where polyclonal antibody technology offers unique capabilities in areas of significant unmet medical need.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19, is being developed with initial funding supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB). In addition to COVID-19, the company’s pipeline also includes programs in Type 1 diabetes, organ transplant and influenza. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005549/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology from TII, Extending Confidential AI Across the Full Lifecycle with Post-Quantum Protection4.5.2026 10:23:00 CEST | Press release
New capabilities make it possible to safely deploy AI agents on the most sensitive and regulated data — with hardware-enforced, verifiable rules and cryptographic guarantees built to withstand quantum computing OPAQUE, the Confidential AI company headquartered in San Francisco, California, today announced it has acquired advanced cryptographic AI technologies from the Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi's Advanced Technology Research Council (ATRC). The acquired technology — already proven in real-world use cases — adds two critical capabilities to OPAQUE's platform: confidential AI model training powered by advanced cryptographic techniques such as multi-party computation and fully homomorphic encryption, as well as post-quantum cryptographic protections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504705475/en/ OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology
Forbes Includes Philip Morris International in Its Net Zero Leaders List4.5.2026 10:00:00 CEST | Press release
PMI ranks number 4, marking its fourth consecutive year of recognition for making significant strides toward reaching net zero carbon footprint goals Philip Morris International (PMI) (NYSE: PM) has been included once more in Forbes’ 2026 Net Zero Leaders1 list, recognizing its leadership and continued progress in advancing climate action across its global operations. The Forbes Net Zero Leaders list highlights U.S. publicly listed companies best positioned to achieve net zero emissions by 2050, based on measurable performance rather than commitments alone. Despite most companies aligning to a 2050 net zero horizon, PMI remains committed to reaching net zero by 2040, as set out in its Climate Transition Plan published in 2025. This aspiration reflects PMI’s confidence in collective progress, trust that ambition drives innovation, that policy will evolve to enable change, and collaboration will accelerate system‑wide transformation. Above all, it signals hope: that by acting early and h
Mobius Renewables Acquires Air Liquide’s Biogas Production Activities in the United States, France, Norway, and Sweden4.5.2026 08:45:00 CEST | Press release
Mobius Renewables today announced the closing of the acquisition of Air Liquide’s biogas production activities in the United States, France, Norway, and Sweden. The acquisition includes six operating landfill gas-to-RNG (Renewable Natural Gas) sites in the U.S., five operating farm waste sites in France, and a 51% interest in Redo Biosolutions with production and distribution assets across Norway and Sweden. The acquired portfolio will be a meaningful addition to Mobius Renewables (“the Company”), a global, vertically integrated low carbon fuels platform established in December 2025 by funds managed by IFM Investors to accelerate the development, production, distribution, and commercialization of RNG at scale across North America and Europe. The Company is headquartered in Houston, Texas with additional offices in the United States, France, Norway, and Sweden. With this transaction, the establishment of Mobius Renewables is complete, and GreenGasUSA and the acquired portfolio will oper
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom